Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 4 (April)

1. High cyclin B1 expression is associated with poor survival in breast cancer.
   Br J Cancer, 100(7): 1055-60. [Abstract] [Full-text]
2. Breast density and outcome of mammography screening: a cohort study.
   Br J Cancer, 100(7): 1205-8. [Abstract] [Full-text]
3. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer.
   Br J Cancer, 100(7): 1061-7. [Abstract] [Full-text]
4. Evaluation of extension of breast screening to women aged 65-70 in England using screening performance measures.
   Br J Cancer, 100(7): 1043-7. [Abstract] [Full-text]
5. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience.
   Br J Cancer, 100(7): 1048-54. [Abstract] [Full-text]
6. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase.
   Int J Cancer, 124(11): 2568-76. [Abstract] [Full-text]
7. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study.
   Cancer Immunol Immunother, 58(6): 887-900. [Abstract] [Full-text]
8. HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness.
   Cell Stress Chaperones, 14(3): 301-10. [Abstract] [Full-text]
9. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
   Cancer Immunol Immunother, 58(6): 915-30. [Abstract] [Full-text]
10. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
    Exp Mol Pathol, 86(2): 95-100. [Abstract] [Full-text]
11. Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population.
    Mayo Clin Proc, 84(4): 317-22. [Abstract] [Full-text]
12. Effect of breast-duct anatomy and wound-healing responses on local tumour recurrence after primary surgery for early breast cancer.
    Lancet Oncol, 10(4): 425-9. [Abstract] [Full-text]
13. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
    Lancet Oncol, 10(4): 381-90. [Abstract] [Full-text]
14. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells.
    Carcinogenesis, 30(4): 575-9. [Abstract] [Full-text]
15. 15-Deoxy-Delta12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS.
    Carcinogenesis, 30(4): 645-54. [Abstract] [Full-text]
16. Grape seed extract inhibits VEGF expression via reducing HIF-1alpha protein expression.
    Carcinogenesis, 30(4): 636-44. [Abstract] [Full-text]
17. Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity.
    Eur J Surg Oncol, 35(5): 469-74. [Abstract] [Full-text]
18. Axillary recurrence after negative sentinel lymph node biopsy under local anesthesia in breast cancer.
    Eur J Surg Oncol, 35(5): 464-8. [Abstract] [Full-text]
19. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
    Eur J Surg Oncol, 35(5): 475-80. [Abstract] [Full-text]
20. Incidental breast masses detected by computed tomography: are any imaging features predictive of malignancy?
    Clin Radiol, 64(5): 529-33. [Abstract] [Full-text]
21. Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
    Biochemistry, 48(14): 3176-85. [Abstract] [Full-text]
22. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.
    Expert Rev Mol Med, 11: e12. [Abstract] [Full-text]
23. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.
    Proc Natl Acad Sci U S A, 106(14): 5837-41. [Abstract] [Full-text]
24. Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy.
    Cancer Invest, 27(4): 417-29. [Abstract] [Full-text]
25. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells.
    Oncogene, 28(14): 1706-13. [Abstract] [Full-text]
26. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin.
    Cancer Invest, 27(4): 397-401. [Abstract] [Full-text]
27. Statins and breast cancer: may matrix metalloproteinase be the missing link.
    Cancer Invest, 27(4): 466-70. [Abstract] [Full-text]
28. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies.
    J Clin Oncol, 27(11): 1899-905. [Abstract] [Full-text]
29. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
    J Clin Oncol, 27(11): 1753-60. [Abstract] [Full-text]
30. FOXP3 expression and overall survival in breast cancer.
    J Clin Oncol, 27(11): 1746-52. [Abstract] [Full-text]
31. Weighing the benefits and burdens of mammography screening among women age 80 years or older.
    J Clin Oncol, 27(11): 1774-80. [Abstract] [Full-text]
32. Investigation of helical tomotherapy for partial-breast irradiation of prone-positioned patients.
    Int J Radiat Oncol Biol Phys, 74(1): 275-82. [Abstract] [Full-text]
33. Trends and patterns of breast conservation treatment in Hong Kong: 1994-2007.
    Int J Radiat Oncol Biol Phys, 74(1): 98-103. [Abstract] [Full-text]
34. Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality.
    Int J Radiat Oncol Biol Phys, 74(1): 73-80. [Abstract] [Full-text]
35. Postmastectomy chest wall radiation to a temporary tissue expander or permanent breast implant--is there a difference in complication rates?
    Int J Radiat Oncol Biol Phys, 74(1): 81-5. [Abstract] [Full-text]
36. Breast cancer regional radiation fields for supraclavicular and axillary lymph node treatment: is a posterior axillary boost field technique optimal?
    Int J Radiat Oncol Biol Phys, 74(1): 86-91. [Abstract] [Full-text]
37. Predictors for clinical outcomes after accelerated partial breast intensity-modulated radiotherapy.
    Int J Radiat Oncol Biol Phys, 74(1): 92-7. [Abstract] [Full-text]
38. Effectiveness of Cultivando la Salud: a breast and cervical cancer screening promotion program for low-income Hispanic women.
    Am J Public Health, 99(5): 936-43. [Abstract] [Full-text]
39. Quantitative measurement of endogenous estrogen metabolites, risk-factors for development of breast cancer, in commercial milk products by LC-MS/MS.
    J Chromatogr B Analyt Technol Biomed Life Sci, 877(13): 1327-34. [Abstract] [Full-text]
40. Racial disparities in breast cancer survival: an analysis by age and stage.
    J Surg Res, 153(1): 105-13. [Abstract] [Full-text]
41. A woman's influence to choose mastectomy as treatment for breast cancer.
    J Surg Res, 153(1): 128-31. [Abstract] [Full-text]
42. The acellular fraction of stored platelets promotes tumor cell invasion.
    J Surg Res, 153(1): 132-7. [Abstract] [Full-text]
43. Vitamin E increases biomarkers of estrogen stimulation when taken with tamoxifen.
    J Surg Res, 153(1): 143-7. [Abstract] [Full-text]
44. Phase contrast imaging of breast tumours with synchrotron radiation.
    Appl Radiat Isot, 67(6): 1033-41. [Abstract] [Full-text]
45. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.
    Steroids, 74(7): 586-94. [Abstract] [Full-text]
46. Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation.
    Steroids, 74(7): 573-6. [Abstract] [Full-text]
47. Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy.
    Eur J Cancer, 45(7): 1274-81. [Abstract] [Full-text]
48. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
    Eur J Cancer, 45(7): 1153-61. [Abstract] [Full-text]
49. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients.
    Br J Cancer, 100(8): 1277-86. [Abstract] [Full-text]
50. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
    Am J Clin Pathol, 131(5): 678-82. [Abstract] [Full-text]
51. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.
    Oncogene, 28(15): 1812-20. [Abstract] [Full-text]
52. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes.
    J Nutr, 139(5): 993-1001. [Abstract] [Full-text]
53. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5).
    Mol Cancer Res, 7(4): 462-75. [Abstract] [Full-text]
54. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study.
    J Clin Oncol, 27(12): 2007-14. [Abstract] [Full-text]
55. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
    J Clin Oncol, 27(12): 1999-2006. [Abstract] [Full-text]
56. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1.
    Exp Cell Res, 315(8): 1490-504. [Abstract] [Full-text]
57. What is the point: will screening mammography save my life?
    BMC Med Inform Decis Mak, 9: 18. [Abstract] [Full-text]
58. Comparative expression pathway analysis of human and canine mammary tumors.
    BMC Genomics, 10: 135. [Abstract] [Full-text]
59. Intramammary lymph nodes: patterns of discovery and clinical significance.
    Surgery, 145(5): 495-9. [Abstract] [Full-text]
60. Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues.
    J Histochem Cytochem, 57(5): 477-89. [Abstract] [Full-text]
61. Dietary carotenoids and the risk of invasive breast cancer.
    Int J Cancer, 124(12): 2929-37. [Abstract] [Full-text]
62. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.
    Int J Cancer, 124(12): 2893-8. [Abstract] [Full-text]
63. Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression.
    Int J Cancer, 124(12): 2813-28. [Abstract] [Full-text]
64. Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.
    Int J Cancer, 124(12): 2829-36. [Abstract] [Full-text]
65. Rab11-FIP3 is a Rab11-binding protein that regulates breast cancer cell motility by modulating the actin cytoskeleton.
    Eur J Cell Biol, 88(6): 325-41. [Abstract] [Full-text]
66. FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion.
    J Cell Biol, 185(2): 357-70. [Abstract] [Full-text]
67. Perspectives on the soy-breast cancer relation.
    Am J Clin Nutr, 89(5): 1673S-1679S. [Abstract] [Full-text]
68. Dietary change and reduced breast cancer events among women without hot flashes after treatment of early-stage breast cancer: subgroup analysis of the Women's Healthy Eating and Living Study.
    Am J Clin Nutr, 89(5): 1565S-1571S. [Abstract] [Full-text]
69. Genomic profiling of breast cancer.
    J Surg Oncol, 99(6): 386-92. [Abstract] [Full-text]
70. The influence of a gene expression profile on breast cancer decisions.
    J Surg Oncol, 99(6): 319-23. [Abstract] [Full-text]
71. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy.
    J Surg Oncol, 99(6): 356-60. [Abstract] [Full-text]
72. Role of breast MRI in the preoperative evaluation of patients with newly diagnosed breast cancer.
    AJR Am J Roentgenol, 192(5): 1438-44. [Abstract] [Full-text]
73. Src supports UDP-glucuronosyltransferase-2B7 detoxification of catechol estrogens associated with breast cancer.
    Biochem Biophys Res Commun, 382(4): 651-6. [Abstract] [Full-text]
74. Pigmented Paget disease--a diagnostic pitfall mimicking melanoma.
    Am J Dermatopathol, 31(3): 223-6. [Abstract] [Full-text]
75. Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.
    Biochem J, 420(1): 37-47. [Abstract] [Full-text]
76. Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function.
    Oncogene, 28(16): 1843-52. [Abstract] [Full-text]
77. Cytoskeletal role in differential adhesion patterns of normal fibroblasts and breast cancer cells inside silicon microenvironments.
    Biomed Microdevices, 11(3): 585-95. [Abstract] [Full-text]
78. Deformability study of breast cancer cells using microfluidics.
    Biomed Microdevices, 11(3): 557-64. [Abstract] [Full-text]
79. Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease.
    DNA Cell Biol, 28(5): 265-9. [Abstract] [Full-text]
80. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population.
    DNA Cell Biol, 28(5): 259-63. [Abstract] [Full-text]
81. Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells.
    Cancer Lett, 278(2): 210-9. [Abstract] [Full-text]
82. Economic, racial and ethnic disparities in breast cancer in the US: towards a more comprehensive model.
    Health Place, 15(3): 855-64. [Abstract] [Full-text]
83. Compression therapy in breast cancer-related lymphedema: A randomized, controlled comparative study of relation between volume and interface pressure changes.
    J Vasc Surg, 49(5): 1256-63. [Abstract] [Full-text]
84. Early breast cancer.
    Lancet, 373(9673): 1463-79. [Abstract] [Full-text]
85. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer.
    Am J Surg, 197(5): 637-41; discussion 641-2. [Abstract] [Full-text]
86. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients.
    Am J Surg, 197(5): 629-32; discussion 632. [Abstract] [Full-text]
87. Gastric malignancies in breast cancer survivors: pathology and outcomes.
    Am J Surg, 197(5): 633-6. [Abstract] [Full-text]
88. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
    Am J Surg Pathol, 33(5): 759-67. [Abstract] [Full-text]
89. Tubular carcinoma of the breast: results of a large contemporary series.
    Am J Surg, 197(5): 674-7. [Abstract] [Full-text]
90. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.
    Am J Pathol, 174(5): 1756-65. [Abstract] [Full-text]
91. Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells.
    J Surg Res, 153(2): 210-6. [Abstract] [Full-text]
92. Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases.
    J Magn Reson Imaging, 29(5): 1154-62. [Abstract] [Full-text]
93. Microperfusion-induced elevation of ADC is suppressed after contrast in breast carcinoma.
    J Magn Reson Imaging, 29(5): 1080-4. [Abstract] [Full-text]
94. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
    J Magn Reson Imaging, 29(5): 1071-9. [Abstract] [Full-text]
95. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues.
    Lab Invest, 89(5): 597-606. [Abstract] [Full-text]
96. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
    Eur J Cancer, 45(8): 1397-406. [Abstract] [Full-text]
97. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases.
    Eur J Cancer, 45(8): 1381-8. [Abstract] [Full-text]
98. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband.
    Br J Cancer, 100(9): 1508-12. [Abstract] [Full-text]
99. Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy?
    Br J Cancer, 100(9): 1486-91. [Abstract] [Full-text]
100. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity.
     Br J Cancer, 100(9): 1393-9. [Abstract] [Full-text]
101. Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies.
     Br J Cancer, 100(9): 1492-8. [Abstract] [Full-text]
102. Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data.
     Radiology, 251(2): 347-58. [Abstract] [Full-text]
103. Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system.
     Radiology, 251(2): 339-46. [Abstract] [Full-text]
104. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.
     Adv Drug Deliv Rev, 61(5): 381-7. [Abstract] [Full-text]
105. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy.
     J Clin Oncol, 27(13): 2151-6. [Abstract] [Full-text]
106. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
     J Clin Oncol, 27(13): 2177-84. [Abstract] [Full-text]
107. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
     J Clin Oncol, 27(13): 2185-91. [Abstract] [Full-text]
108. Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer.
     Jpn J Clin Oncol, 39(5): 284-9. [Abstract] [Full-text]
109. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
     J Clin Oncol, 27(13): 2163-9. [Abstract] [Full-text]
110. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.
     J Clin Oncol, 27(13): 2170-6. [Abstract] [Full-text]
111. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
     J Clin Oncol, 27(13): 2157-62. [Abstract] [Full-text]
112. Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer.
     Ann Surg, 249(5): 828-33. [Abstract] [Full-text]
113. The value of level III clearance in patients with axillary and sentinel node positive breast cancer.
     Ann Surg, 249(5): 834-9. [Abstract] [Full-text]
114. Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling.
     Ann Oncol, 20(5): 874-8. [Abstract] [Full-text]
115. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
     Ann Oncol, 20(5): 816-27. [Abstract] [Full-text]
116. Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality.
     Ann Oncol, 20(5): 857-61. [Abstract] [Full-text]
117. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
     Ann Oncol, 20(5): 868-73. [Abstract] [Full-text]
118. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
     Ann Oncol, 20(5): 862-7. [Abstract] [Full-text]
119. HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer.
     J Cancer Res Clin Oncol, 135(6): 807-13. [Abstract] [Full-text]
120. Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
     J Cancer Res Clin Oncol, 135(6): 823-7. [Abstract] [Full-text]

© 2004-2010 Breast Cancer Research Today. All Rights Reserved.